IMV’s Ovarian Cancer Trial Testing Triple Combo Therapy Doses First Patient

IMV’s Ovarian Cancer Trial Testing Triple Combo Therapy Doses First Patient
The Phase 1b/2 trial investigating IMV lead candidate DPX-Survivac in combination with Incyte‘s experimental epacadostat and low-dose chemotherapy in recurrent ovarian cancer patients has completed patient enrollment in the study’s first part, the companies announced. It also dosed the first patient in the trial’s second part. “Completion of the Phase 1b enrollment and initiation of the Phase 2

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *